Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  EntreMed Inc    

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Develops pharmaceutical drugs for treating cancer and inflammatory diseases

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs with commercial focus on the China market.

The Company operates through one business segment, which is the development of targeted therapeutics primarily for the treatment of cancer.

The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau.

The drugs are Captisol-Enabled, ZEVALIN and MARQIBO.

CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.
Managers
NameAgeSinceTitle
Ken Keyong Ren MD, PhD572012Chief Executive Officer & Director
Wei-Wu He PhD, MBA512012Executive Chairman
Cynthia Wong Hu462006COO, Secretary, Vice President & General Counsel
Sara B. Capitelli, CPA492011Chief Accounting Officer & Vice President-Finance
Rong Chen MD, PhD-2015Chief Medical Officer
Tak W. Mak, PhD692012Director
Zuie Chin Huang, MBA502013Independent Director
Yue Alexander Wu PhD, MBA522013Independent Director
Franklin Cary Salisbury, Jr.602014Independent Director
Rajesh C. Shrotriya, MD722014Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 42,662,846 20,816,156 48.8% 79,545 0.2% 48.8%
Shareholders
NameEquities%
Spectrum Pharmaceuticals, Inc. 7,094,259 16.7%
IDG Capital Partners Co., Ltd. 6,842,783 16.1%
He Xie Ai Qi Investment Management Beijing Co. Ltd. 4,744,910 11.1%
Zhejiang Kanglaite Group Co. Ltd. 2,057,613 4.83%
Wellington Shields & Co. LLC 489,327 1.15%
Wellington Shields Capital Management LLC 465,359 1.09%
Emerging Technology Partners LLC 441,072 1.04%
Kleiner Perkins Caufield & Byers LLC 416,666 0.98%
The Vanguard Group, Inc. 382,698 0.90%
Tak W. Mak, PhD 365,376 0.86%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
INCYTE CORPORATIO..
CELLTRION, INC.
LONZA GROUP AG
QUINTILES TRANSNA..
ALKERMES PLC
ALNYLAM PHARMACEU..
QIAGEN NV
SEATTLE GENETICS,..
IONIS PHARMACEUTI..
UNITED THERAPEUTI..
CHARLES RIVER LAB..
ICON PLC
ACADIA PHARMACEUT..
BIO-TECHNE CORP
PAREXEL INTERNATI..
BB BIOTECH AG
-
INTREXON CORP
PRA HEALTH SCIENC..
ANACOR PHARMACEUT..
INC RESEARCH HOLD..
Sector Biotechnology & Medical Research
EntreMed Inc : Connections
Intradigm Corp.
OriGene Technologies, Inc.
Smooth Prosper Ltd.
Cytomyx Holdings Plc
Chiral Quest (Suzhou) Co. Ltd.
ImmunoVentis, Inc.
Crown Bioscience, Inc.
Amnis Corp.
MithraGen, Inc.
CVie Therapeutics Co. Ltd.
Wuhan Kindstar Diagnostics Co., Ltd.
Emerging Technology Partners LLC
Miikana Therapeutics, Inc.
Zenesis Ltd.
The Campbell Family Institute for Breast Cancer Research
OMNI Pharmaceuticals (USA), Inc.
University of Toronto
KPCB China Fund II LP
American Academy of Arts & Sciences
National Foundation for Cancer Research
National Academy of Sciences
Allos Therapeutics, Inc.
Company contact information
CASI Pharmaceuticals, Inc.
9620 Medical Center Drive
Suite 300
Rockville, MD 20850

Phone : +1.240.864.2600
Fax : +1.240.315.2437
Web : www.casipharmaceuticals.com
© 2016 People , Fundamentals and Ownership